| Over a month ago | ||||
Scotiabank analyst Adam… Scotiabank analyst Adam Buckham lowered the firm's price target on Well Health Technologies to C$7.50 from C$9 and keeps an Outperform rating on the shares. | ||||
TD Securities analyst… TD Securities analyst David Kwan lowered the firm's price target on Well Health Technologies to C$7 from C$9 and keeps a Buy rating on the shares. | ||||
| Over a quarter ago | ||||
Canaccord analyst Doug… Canaccord analyst Doug Taylor lowered the firm's price target on Well Health Technologies to C$10 from C$12 and keeps a Buy rating on the shares. | ||||
CIBC analyst Scott… CIBC analyst Scott Fletcher lowered the firm's price target on Well Health Technologies to C$8 from C$11 and keeps an Outperformer rating on the shares. | ||||
CIBC analyst Scott… CIBC analyst Scott Fletcher raised the firm's price target on Well Health Technologies to C$11 from C$10.50 and keeps an Outperformer rating on the shares. | ||||
Scotiabank analyst Adam… Scotiabank analyst Adam Buckham lowered the firm's price target on Well Health Technologies to C$9 from C$10 and keeps an Outperform rating on the shares. | ||||
TD Securities analyst… TD Securities analyst David Kwan raised the firm's price target on Well Health Technologies to C$11 from C$10.50 and keeps a Buy rating on the shares. | ||||
Scotiabank analyst Adam… Scotiabank analyst Adam Buckham upgraded Well Health Technologies to Outperform from Sector Perform with a price target of C$9, down from C$10. Q3 results displayed positive underlying trends and "for the most part" beat his and Street estimates across the board, Buckham said. Given that shares are off 32% from their year-to-date highs, he sees the current valuation as an attractive entry point, Buckham tells investors. | ||||
Canaccord analyst Doug… Canaccord analyst Doug Taylor upgraded Well Health Technologies to Buy from Speculative Buy with an unchanged price target of C$12, citing improved profit stability after the company's Q3 results came in ahead of expectations and the company updated its outlook. Well Health is now producing consistent profitability and cash flow on a revenue base described as 93% recurring or re-occurring, reducing the risk profile, Taylor said. | ||||
CIBC analyst Scott… CIBC analyst Scott Fletcher lowered the firm's price target on Well Health Technologies to C$10.50 from C$11.50 and keeps an Outperformer rating on the shares. | ||||
